Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont

Aubagne, France | July 2, 2019

This announcement contains corrections of the figures given in our half-year report of the liquidity contract published yesterday.

Under the liquidity contract concluded between SARTORIUS STEDIM BIOTECH and the stockbroker Gilbert Dupont, the following assets appeared on the liquidity account on June 28, 2019:

- Number of shares: 2,519
- Liquidity account cash balance: €468,433.16

During the first half of 2019, the following were negotiated:

<table>
<thead>
<tr>
<th>ORDER INTAKE</th>
<th>72,168 securities</th>
<th>€7,778,802.43</th>
<th>2,404 transactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>SALES</td>
<td>73,065 securities</td>
<td>€7,889,953.10</td>
<td>2,522 transactions</td>
</tr>
</tbody>
</table>

It should be noted that in the second half of 2018, which ended December 31, 2018, the following assets appeared on the liquidity account:

- Number of shares: 3,416
- Liquidity account cash balance: €357,282.50

It should also be noted that upon implementing the liquidity contract, the following assets were made available:

- Number of shares: 654
- Liquidity account cash balance: €394,895.12

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2018, the company earned sales revenue of €1,212.2 million and currently employs some 5,800 people.

Contact
Ben Orzelek
Investor Relations
+49(0)551.308.1668